Mr. Harel, General Partner at Pitango Venture Capital is a veteran of the life sciences industry. He has fifteen years of experience, covering a wide range of activities, from basic business and technology development to corporate executive management, in areas such as pharmaceutical development, drug delivery, medical devices and diagnostics.
Before joining Pitango, Mr. Harel was Director of Corporate Development at Nektar Therapeutics (NASDAQ: NKTR) where he was responsible for strategic planning, in-licensing and M&A activities. Prior to his role at Nektar, he held various management positions at leading companies both in Israel and in the U.S. including IDEXX Laboratories (NASDAQ: IDXX) and IDGene Pharmaceuticals.
Mr. Soderberg is the Managing Partner of Worthy Ventures Resources, LLC, a private investment company he founded in February 2010.
Mr. Soderberg is also a Board Member of Greatbatch Inc. (NYSE: GB) and Chairman of the Board of HealthSense . Mr. Soderberg retired in January 2010 as President and Chief Executive Officer of Hill-Rom Holdings, Inc. (NYSE: HRC), a position he held since March 2006. Prior to that , he was President and Chief Executive Officer of Welch Allyn, Inc., and for the seven years prior to that, Chief Operating Officer of Welch Allyn’s medical products business.
Mr. Soderberg also held a number of positions over a twenty-three year career with Johnson & Johnson, where his final position was President of one of its operating subsidiaries. He had also served on the Board of Directors of Hill-Rom (formerly Hillenbrand Industries) and AdvaMed. Mr. Soderberg is a former Director of Constellation Brands, Inc. (NYSE: STZ) and Welch Allyn, Inc.
Mr. Barr earned his experience serving at some innovative and successful medical device companies. He was most recently Executive Vice President and President of Global Surgical at Bausch & Lomb Holdings Incorporated until the acquisition of Bausch and Lomb by Valeant Pharmaceuticals in 2013. Prior to Bausch and Lomb, Barr was the CEO of AGA Medical, pioneer and leader in minimally invasive devices to repair structural heart defects and other vascular defects. Mr. Barr led a IPO for the Company in 2009 and the business was sold to St. Jude Medical in 2010.
Mr. Barr is a graduate of the J. L. Kellogg Graduate School of Management-Northwestern University where he earned his Master’s degree in finance, accounting and economics. He earned his undergraduate degree in bioengineering from the University of Pennsylvania.
Dr. Shinar is a scientist and medical device entrepreneur. He is the former President and CEO of X-Technologies Inc., an interventional cardiology company that was sold to Guidant Corp. in 2003. He serves on the board of Dune Medical Devices, an Apax Partners Portfolio Company.
Dr. Shinar holds a Ph. D. in physics from the Weizmann Institute of Science, as well as an MBA from INSEAD. He is a graduate of the IDF Talpiot Project.
Dr. Makover has managed venture capital investments in the biotech/ medical devices field for the past eight years, and joined ProSeed in 2006. Previously she held senior management positions in life sciences companies focusing on drugs, diagnostics and tissue engineering,Holding positions of CEO and Board Member, R&D, Process Development and Production Manager, Dr. Makover had responsibility for both technology and business aspects.
Dr. Makover holds a joint Ph.D degree in life sciences from Columbia University (USA) and Weizmann Institute of Science, (Israel) and did post- doctoral research at the Weizmann Institute in Israel. Dr. Makover also holds an MBA degree from Bar-Ilan University.
Mr. Goldin joined Docor International Management in 2004. Prior to joining Docor, he served as a Director of Investments and Analysis at Inventech Venture Capital, a public company which is traded on the Tel Aviv Stock Exchange.
Before working at Inventech, Mr. Goldin practiced law at Israeli, Blustein, Kogan & Co. In addition, he was part of the teaching staff of the MBA program run jointly by Tel Aviv University and Northwestern University`s Kellogg School of Management (Chicago, USA). Mr. Goldin participated in the International Marketing Program and the Global Consulting Program, a joint project of Pennsylvania University`s Wharton Business School and Tel Aviv University`s Business School. Mr. Goldin is an associate of the Israel Bar Association.
He holds MA and BA degrees in Economics, both with outstanding honors, and an LLB in Law, all from Tel Aviv University.
Ms. Ciehanover is Managing General Partner at Challenge II investment fund ($120M). Prior to serving in this role Ms. Ciehanover held several key positions in Challenge Funds I and II, including Vice President, Executive Vice President, and Co-Managing General Partner.
Ms. Ciehanover served as chairperson of the Board of Directors of Sol-Gel Technologies and member of several board of directors of the funds’ portfolio companies. Presently she is also a board member of Export Investment Company Ltd. (TASE:EXPO).
Previously, , Ms. Ciehanover worked as a corporate attorney at the law firm of Proskauer Rose Goetz and Mendelsohn in New York.
Prior to joining the funds, Ms. Ciehanover served as a consultant at Intercon Inc., a New York-based investment and consulting firm specializing in the Entertainment Industry. She holds an M.B.A. from Columbia University and an LL.B. in Corporate Law from Israel’s Bar-Ilan University Law School and membership in both the New York and Israeli Bar Associations.
Mr. Halperin is a veteran high tech executive. He has served in several senior management positions including CEO of Emmunet, VP Marketing at Radcom (NASDAQ: RDCM), and VP of Business Development at Lenslet.
He also worked as the R&D Manager at Eldat and was the Department Head of an R&D Unit in the IDF Intelligence Corps, where he participated in the Talpiot Project.
Mr. Halperin earned an M.Sc. in Applied Physics from Tel Aviv University and an MBA from the MIT Sloan Fellows Executive MBA Program.